Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 9Terminated 5Unknown 4Recruiting 4Withdrawn 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 43Stomach Neoplasms 42Rectal Neoplasms 28Pancreatic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 13Colonic Neoplasms 13Cholangiocarcinoma 11Neoplasm Metastasis 10Adenocarcinoma 10Neoplasms 9Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 7Biliary Tract Neoplasms 7Locally Advanced Rectal Cancer 6Gastrointestinal Neoplasms 6Gallbladder Neoplasms 6Esophageal Neoplasms 6Adenocarcinoma Of Esophagus 6Peritoneal Neoplasms 5Recurrence 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 3Carcinoma 3Bile Duct Neoplasms 3Appendiceal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Pathologic Complete Response 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

Cyclophosphamide 23venetoclax 17Dexamethasone 16pembrolizumab 15fludarabine 15Cytarabine 13pomalidomide 8Rituximab 8Gemcitabine 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7selinexor 6Paclitaxel 6Injections 6Immunotherapy, Adoptive 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Oxaliplatin 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Oxaliplatin × Clear all
NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Fudan University

Phase 2 Recruiting
130 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05476796 2024-10-24

LOGICAN

UNICANCER

Phase 2 Recruiting
118 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT02889666 2024-04-17

CCODG-NSCLC

Shanghai Jiao Tong University School of Medicine

Phase 1 Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡